Comparative Biosciences

Established in 1996, Comparative Biosciences was created to deliver specialized scientific expertise and high-quality service to the biomedical and biopharmaceutical sectors. Our range of services encompasses extensive experience in GLP and non-GLP preclinical toxicology, efficacy, pharmacology, pharmacokinetics-pharmacodynamics, histopathology, and safety studies across all laboratory species. Furthermore, we specialize in ocular, dermatology, fibrosis, otic/ototoxicity, wound healing, burns, stem cells, oncology, renal, ophthalmology, inflammation, immune-mediated models, cardiovascular and pulmonary studies, infection models and devices, as well as contract histopathology, immunohistochemistry, and custom model development. CBI stands at the forefront of conducting challenging and distinctive IND-enabling research studies, including those involving stem cells, stem cell and device combinations, delivery systems, diabetes, and cancer therapies. Our AAALAC-accredited facility is fully equipped with an in-house histopathology laboratory and a full-time quality assurance unit. We are registered with the FDA, USDA, and OLAW, and our clientele varies from small biomedical firms to pharmaceutical giants, academia, defense, and government.